{"id":"NCT00732615","sponsor":"Shire","briefTitle":"Use of NPSP558 in the Treatment of Hypoparathyroidism","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-18","primaryCompletion":"2011-09-28","completion":"2011-09-28","firstPosted":"2008-08-12","resultsPosted":"2015-03-06","lastUpdate":"2021-06-03"},"enrollment":124,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypoparathyroidism"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"NPSP558","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"50, 75, 100 mcg NPSP558","type":"EXPERIMENTAL"}],"summary":"Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.","primaryOutcome":{"measure":"The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24.","timeFrame":"Week 24 of dosing","effectByArm":[{"arm":"Placebo","deltaMin":2.5,"sd":null},{"arm":"NPSP558","deltaMin":54.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":21},"locations":{"siteCount":31,"countries":["United States","Belgium","Canada","Denmark","France","Hungary","Italy","United Kingdom"]},"refs":{"pmids":["36018496","35974422","35696069","32738041","29099947","24622413"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":40},"commonTop":["Hypocalcaemia","Paraesthesia","Muscle spasms","Headache","Nausea"]}}